Neovasc Inc. (NVCN)

Trade NVCN now with
1/2/2020 8:40:50 AM Neovasc Reports $10 Mln Registered Direct Offering Priced At-The-Market
12/31/2019 7:03:34 AM Neovasc Submits Premarket Approval Application To FDA For Neovasc Reducer Medical Device For Refractory Angina
10/15/2019 7:14:48 AM Neovasc Announces Notice Of US Patent Granted For Tiara Transcatheter Device For Severe Mitral Regurgitation
9/3/2019 8:59:06 AM European Society Of Cardiology Includes Neovasc Reducer For Treatment Of Refractory Angina In European Guidelines
8/22/2019 9:03:23 AM Neovasc Gets Nasdaq Notification Regarding Minimum Market Value Deficiency
6/25/2019 2:42:47 PM Neovasc Regains Compliance With Nasdaq Minimum Market Value Rule
5/9/2019 4:01:57 PM Neovasc Q1 Loss/share $0.21 Vs. Loss $0.38 Year Ago
4/17/2019 7:52:26 AM Neovasc Reducer Improves Diastolic Function In Patients Suffering From Severe Angina
3/21/2019 7:51:33 AM Neovasc Announces German Court's Decision To Dismiss CardiAQ's Claim To Co-inventorship Of European Patent For Tiara
3/15/2019 3:40:40 PM Neovasc Announces Closing Of $5 Mln Public Offering Of Common Shares
3/13/2019 6:22:15 AM Neovasc Unveils Pricing Of $5 Mln Public Offering Of Common Shares
3/12/2019 4:01:54 PM Neovasc Announces Proposed Public Offering Of Common Shares
3/12/2019 9:16:27 AM Neovasc Enters Agreements To Exchange Outstanding Warrants For Shares
2/26/2019 6:06:11 AM Neovasc Reports Pricing Of $5 Mln Public Offering Of Common Shares
2/25/2019 4:13:10 PM Neovasc Begins Proposed Public Offering Of Common Shares
1/29/2019 7:34:59 AM Neovasc Receives Approval To Proceed With Phase 2 Of TIARA-II Study From Clinical Regulators In Germany And The UK
1/22/2019 7:31:14 AM Neovasc Reports Dismissal Of Claim Brought By Edwards Lifesciences
12/11/2018 7:33:32 AM Neovasc Announces Positive 12-year Follow-up Data For Neovasc Reducerâ„¢ As Published In JACC